ABSTRACT
Distinct Notch ligands possess a characteristic ability in terms of functional T cell differentiation. However, the precise role or the therapeutic potential of each Notch ligand in autoimmune diseases is largely unknown. In this study, we examined whether Jagged1 modulates a collagen-induced rheumatoid arthritis (CIA) model by altering T cell responses. The injection of a soluble Jagged1-encoding plasmid, sJag1-P, before or even after initial type II collagen (CII) immunization suppressed the disease severity of CIA. However, this treatment did not suppress CII-specific CD4(+) T cell proliferation and CII-specific Ab production. Depletion of either CD4(+) or CD8(+) T cells ameliorated CIA severity and sJag1-P further improved CIA in CD4(+) but not CD8(+) T cell-depleted mice. Injection of OVA and Jagged1-encoding plasmids inhibited proliferation of OVA-specific granzyme B-producing CD8(+) T cells, although Jagged1 could not directly inhibit CD8(+) T cell proliferation in vitro. The blockade of Jagged1 by an anti-Jagged1 Ab exacerbated CIA, whereas this effect was not observed in the absence of CD8(+) T cells. These data indicate that Jagged1 is able to deliver an indirect negative signal into CD8(+) T cells in vivo, which suggests its therapeutic potential in the treatment of CD8(+) T cell-mediated diseases, including rheumatoid arthritis.
Subject(s)
Arthritis, Experimental/immunology , Arthritis, Experimental/therapy , CD8-Positive T-Lymphocytes/immunology , Calcium-Binding Proteins/physiology , Calcium-Binding Proteins/therapeutic use , Growth Inhibitors/therapeutic use , Intercellular Signaling Peptides and Proteins/physiology , Intercellular Signaling Peptides and Proteins/therapeutic use , Lymphocyte Activation/immunology , Membrane Proteins/physiology , Membrane Proteins/therapeutic use , Signal Transduction/immunology , Animals , Arthritis, Experimental/pathology , CD8-Positive T-Lymphocytes/pathology , Calcium-Binding Proteins/administration & dosage , Calcium-Binding Proteins/genetics , Cell Line , Cells, Cultured , Down-Regulation/genetics , Down-Regulation/immunology , Growth Inhibitors/administration & dosage , Growth Inhibitors/genetics , Growth Inhibitors/physiology , Humans , Intercellular Signaling Peptides and Proteins/administration & dosage , Intercellular Signaling Peptides and Proteins/genetics , Jagged-1 Protein , Jurkat Cells , Lymphocyte Activation/genetics , Lymphocyte Depletion , Male , Membrane Proteins/administration & dosage , Membrane Proteins/genetics , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Plasmids/administration & dosage , Plasmids/genetics , Plasmids/therapeutic use , Serrate-Jagged Proteins , Signal Transduction/genetics , Vaccines, DNA/administration & dosage , Vaccines, DNA/genetics , Vaccines, DNA/therapeutic useABSTRACT
The Long-Evans Cinnamon (LEC) rat has a spontaneous mutation, T helper immunodeficiency (thid), which causes a markedly reduced CD4(+) thymocyte population. Here we positionally clone the locus and identify a deletion in the gene encoding a receptor-like protein tyrosine phosphatase kappa (Ptprk) that led to complete loss of the transcript. The rat Ptprk gene exhibits 98% identity with the human and mouse counterparts and is expressed most abundantly in the CD4(-)CD8(-) double-negative stage. The downregulation of Ptprk in mouse immature thymocytes by RNA interference mimicked the thid phenotype. These results indicate that thid maps to the Ptprk locus and that functional Ptprk is crucial for lineage commitment or progression of CD4(+) T cells. We also found that Ptprk appears to function in parallel with or downstream of Th-POK/cKrox (also known as ZBTB7B), a master regulator of T cell lineage decision.
Subject(s)
Protein Tyrosine Phosphatases/genetics , T-Lymphocytes/metabolism , Animals , Animals, Congenic , Base Sequence , Cell Differentiation , Chromosome Mapping , DNA, Complementary/genetics , Female , Humans , Male , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Organ Culture Techniques , Pregnancy , Protein Tyrosine Phosphatases/antagonists & inhibitors , Protein Tyrosine Phosphatases/metabolism , RNA Interference , Rats , Rats, Inbred LEC , Sequence Deletion , T-Lymphocytes/cytology , T-Lymphocytes/immunology , Thymus Gland/cytology , Thymus Gland/immunology , Thymus Gland/metabolismABSTRACT
It has been reported that Cordyceps sinensis, a traditional Chinese medicine, has various pharmacological effects. The aim of this study was to clarify the effect of water extract of Cordyceps sinensis (WECS) on osteoclast differentiation in vitro. In mouse bone marrow cells and monocyte/macrophage cell line RAW264.7, WECS dose-dependently inhibited the receptor activator of nuclear factor kappa B (NF-kappaB) ligand (RANKL)-induced osteoclast differentiation by tartrate-resistant acid phosphatase (TRAP) staining. In fact, cytotoxic effect was not observed in the RAW264.7 cells treated with WECS. Moreover, the mRNA expression of osteoclast related genes (calcitonin receptor, cathepsin K, matrix metalloprotease 9 and nuclear factor of activated T cells c1) was also inhibited by WECS. Investigation of inhibitory mechanism by using electrophoretic mobility shift assay (EMSA) and Western blot analysis revealed that WECS inhibited the activation of NF-kappaB through the prevention of IkappaBalpha phosphorylation. In conclusion, the present results demonstrate for the first time that WECS is a potent inhibitor of the RANKL-induced osteoclast differentiation through a mechanism involving the NF-kappaB pathway.